| Literature DB >> 23031194 |
Francisco-Javier Gonzalez-Barcala1, Ramon de la Fuente-Cid, Mónica Tafalla, Javier Nuevo, Francisco Caamaño-Isorna.
Abstract
BACKGROUND: The measurement of health-related quality of life (HRQoL) is increasingly recognized as an important endpoint, as a reflection of the effects of the disease from a patient perspective. Our aim was to evaluate the factors determining the HRQoL in patients with asthma, according to the EQ-5D questionnaire.Entities:
Year: 2012 PMID: 23031194 PMCID: PMC3489800 DOI: 10.1186/2049-6958-7-32
Source DB: PubMed Journal: Multidiscip Respir Med ISSN: 1828-695X
Factors associated with health-related quality of life (n = 2,125)
| | |
| Female | 883/1,227 (72.0%) |
| Male | 726/898 (80.8 %) |
| | |
| ≥ 60 years | 335/638 (52.5%) |
| 40 to 59 years | 551/704 (78.3%) |
| 18 to 39 years | 723/783 (92.3%) |
| | |
| ≥ 30 | 243/424 (57.3%) |
| ≥ 25 to 30 | 656/873 (75.1%) |
| < 25 | 709/826 (85.8%) |
| | |
| None | 74/170 (43.5%) |
| Primary | 613/900 (68.1%) |
| Secondary | 600/706 (85.0%) |
| University | 319/345 (92.5%) |
| | |
| Non active worker | 648/1,029 (63.0%) |
| Active worker | 960/1,094 (87.7%) |
| | |
| Lives alone | 145/237 (61.2%) |
| Lives with someone | 1461/1,885 (77.5%) |
| | |
| Rural | 632/859 (73.6%) |
| Urban | 977/1,265 (77.2%) |
| | |
| Yes | 744/984 (75.6%) |
| No | 865/1,141 (75.8%) |
| | |
| Severe persistent | 28/90 (31.1%) |
| Moderate persistent | 449/706 (63.6%) |
| Mild persistent | 655/774 (84.6%) |
| Intermittent | 476/554 (85.9%) |
| | |
| Never | 1006/1,339 (75.1%) |
| Current or former | 601/784 (76.7%) |
| | |
| ≤ 22.5 grams | 705/940 (75.0%) |
| > 22.5 grams | 732/944 (77.5%) |
| | |
| Yes | 473/626 (75.6%) |
| No | 1,134/1,497 (75.7%) |
| | |
| No | 871/1,201 (72.5%) |
| Yes | 738/924 (79.9%) |
| | |
| Yes | 207/307 (67.4%) |
| No | 1,394/1,810 (77.0%) |
| Very poor | 31/40 (77.5%) |
| Poor | 224/313 (71.6%) |
| Acceptable | 624/805 (77.5%) |
| Good | 562/743 (75.6%) |
| Very good | 168/224 (75.0%) |
| | |
| >10 times every month | 51/76 (67.1%) |
| 6-10 times every month | 163/223 (73.1%) |
| 1-5 times every month | 764/999 (76.5%) |
| Never | 631/827 (76.3) |
| < 8 | 388/531 (73.1%) |
| ≥ 8 | 1,220/1,591 (76.7%) |
| | |
| Oral corticosteroids | 62/158 (39.2%) |
| LABA + IC | 1,114/1,476 (75.5%) |
| Inhaled corticosteroids | 180/209 (86.1%) |
| SABA or LABA | 230/255 (90.2%) |
| | |
| >1.50 | 437/792 (55.2%) |
| 0.75-1.50 | 464/561 (82.7%) |
| <0.75 | 708/772 (91.7%) |
| | |
| Very poor | 43/83 (51.8%) |
| Poor | 172/322 (53.4%) |
| Controlled | 504/721 (69.9%) |
| Total control | 889/997 (89.2%) |
| Very poor | 11/41 (26.8%) |
| Poor | 97/191 (50.8%) |
| Controlled | 432/666 (64.9%) |
| Total control | 1,060/1,217 (87.1%) |
| | |
| Yes | 54/179 (30.2%) |
| No | 1,555/1,946 (79.9%) |
| | |
| ≥2 | 10/52 (19.2%) |
| 1 | 44/127 (34.6%) |
| 0 | 1,555/1,946 (79.9%) |
| | |
| Yes | 503/810 (62.1%) |
| No | 1,106/1,315 (84.1%) |
| | |
| ≥3 | 84/213 (39.0%) |
| 1-2 | 419/596 (70.3%) |
| 0 | 1,106/1,315 (84.1%) |
| | |
| No | 97/112 (86.6%) |
| Yes | 1,506/2,012 (75.1%) |
| | |
| 0 | 97/112 (86.6%) |
| < 4 | 675/786 (85.9%) |
| ≥ 4 | 831/1,221 (68.1%) |
Factors associated with health-related quality of life, according dimensions of EuroQol-5D questionnaire (n = 2,125)
| Female | 883/1,227 (72.0%) | 1 |
| Male | 726/898 (80.8%) | 1.49 (1.13,1.97) |
| ≥ 60 years | 335/638 (52.5%) | 1 |
| 40 to 59 years | 551/704 (78.3%) | 1.96 (1.41,2.73) |
| 18 to 39 years | 723/783 (92.3%) | 4.13 (2.71,6.32) |
| ≥ 30 | 243/424 (57.3%) | 1 |
| ≥ 25 to 30 | 656/873 (75.1%) | 1.64 (1.20,2.23) |
| < 25 | 709/826 (85.8%) | 2.14 (1.50,3.04) |
| None | 74/170 (43.5%) | 1 |
| Primary | 613/900 (68.1%) | 1.46 (0.97,2.20) |
| Secondary | 600/706 (85.0%) | 1.77 (1.10,2.85) |
| University | 319/345 (92.5%) | 3.19 (1.73,5.88) |
| Non active worker | 648/1,029 (63.0%) | 1 |
| Active worker | 960/1,094 (87.7%) | 1.43 (1.04,1.97) |
| Lives alone | 145/237 (61.2%) | 1 |
| Lives with someone | 1,461/1,885 (77.5%) | 1.60 (1.10,2.33) |
| >1.50 | 437/792 (55.2%) | 1 |
| 0.75-1.50 | 464/561 (82.7%) | 2.68 (1.96,3.66) |
| <0.75 | 708/772 (91.7%) | 4.83 (3.37,6.92) |
| Yes | 54/179 (30.2%) | 1 |
| No | 1,555/1,946 (79.9%) | 2.64 (1.71,4.07) |
| ≥ 60 years | 335/638 (52.5%) | 1 |
| 40 to 59 years | 551/704 (78.3%) | 2.25 (1.34,3.75) |
| 18 to 39 years | 723/783 (92.3%) | 4.30 (1.93,9.54) |
| None | 74/170 (43.5%) | 1 |
| Primary | 613/900 (68.1%) | 3.08 (1.89,5.03) |
| Secondary | 600/706 (85.0%) | 2.71 (1.40,5.24) |
| University | 319/345 (92.5%) | 3.21 (1.20,8.54) |
| Non active worker | 648/1,029 (63.0%) | 1 |
| Active worker | 960/1,094 (87.7%) | 2.77 (1.52,5.04) |
| Lives alone | 145/237 (61.2%) | 1 |
| Lives with someone | 1,461/1,885 (77.5%) | 1.70 (1.03,2.80) |
| Severe persistent | 28/90 (31.1%) | 1 |
| Moderate persistent | 449/706 (63.6%) | 1.81 (0.98,3.34) |
| Mild persistent | 655/774 (84.6%) | 3.32 (1.61,6.85) |
| Intermittent | 476/554 (85.9%) | 3.21 (1.38,7.46) |
| Yes | 207/307 (67.4%) | 1 |
| No | 1,394/1,810 (77.0%) | 1.99 (1.22,3.26) |
| Oral corticosteroids | 62/158 (39.2%) | 1 |
| LABA + IC | 1,114/1,476 (75.5%) | 1.34 (0.77,2.32) |
| Inhaled corticosteroids | 180/209 (86.1%) | 4.07 (1.07,15.48) |
| SABA or LABA | 230/255 (90.2%) | 1.76 (0.58,5.33) |
| >1.50 | 437/792 (55.2%) | 1 |
| 0.75-1.50 | 464/561 (82.7%) | 2.49 (1.43,4.36) |
| <0.75 | 708/772 (91.7%) | 2.69 (1.41,5.14) |
| Yes | 54/179 (30.2%) | 1 |
| No | 1,555/1,946 (79.9%) | 2.52 (1.52,4.17) |
| ≥ 60 years | 335/638 (52.5%) | 1 |
| 40 to 59 years | 551/704 (78.3%) | 2.27 (1.63,3.16) |
| 18 to 39 years | 723/783 (92.3%) | 2.67 (1.80,3.95) |
| ≥ 30 | 243/424 (57.3%) | 1 |
| ≥ 25 to 30 | 656/873 (75.1%) | 1.27 (0.93,1.73) |
| < 25 | 709/826 (85.8%) | 1.43 (1.02,2.02) |
| None | 74/170 (43.5%) | 1 |
| Primary | 613/900 (68.1%) | 1.51 (0.99,2.31) |
| Secondary | 600/706 (85.0%) | 1.86 (1.16,2.99) |
| University | 319/345 (92.5%) | 2.62 (1.49,4.60) |
| Lives alone | 145/237 (61.2%) | 1 |
| Lives with someone | 1,461/1,885 (77.5%) | 1.76 (1.23,2.53) |
| Severe persistent | 28/90 (31.1%) | 1 |
| Moderate persistent | 449/706 (63.6%) | 1.75 (0.95,3.24) |
| Mild persistent | 655/774 (84.6%) | 1.97 (1.04,3.74) |
| Intermittent | 476/554 (85.9%) | 1.76 (0.90,3.45) |
| Oral corticosteroids | 62/158 (39.2%) | 1 |
| LABA + IC | 1,114/1,476 (75.5%) | 1.41 (0.88,2.23) |
| Inhaled corticosteroids | 180/209 (86.1%) | 2.43 (1.27,4.62) |
| SABA or LABA | 230/255 (90.2%) | 1.97 (1.05,3.71) |
| >1.50 | 437/792 (55.2%) | 1 |
| 0.75-1.50 | 464/561 (82.7%) | 3.74 (2.79,5.09) |
| <0.75 | 708/772 (91.7%) | 7.48 (5.29,10.58) |
| Yes | 54/179 (30.2%) | 1 |
| No | 1,555/1,946 (79.9%) | 1.75 (1.14,2.68) |
| Yes | 503/810 (62.1%) | 1 |
| No | 1,106/1,315 (84.1%) | 1.67 (1.28,2.17) |
| Female | 883/1,227 (72.0%) | 1 |
| Male | 726/898 (80.8%) | 1.55 (1.17,2.06) |
| ≥ 60 years | 335/638 (52.5%) | 1 |
| 40 to 59 years | 551/704 (78.3%) | 2.32 (1.68,3.22) |
| 18 to 39 years | 723/783 (92.3%) | 5.27 (3.52,7.88) |
| ≥ 30 | 243/424 (57.3%) | 1 |
| ≥ 25 to 30 | 656/873 (75.1%) | 1.36 (1.00,1.85) |
| < 25 | 709/826 (85.8%) | 1.75 (1.25,2.47) |
| None | 74/170 (43.5%) | 1 |
| Primary | 613/900 (68.1%) | 1.59 (1.02,2.49) |
| Secondary | 600/706 (85.0%) | 1.88 (1.14,3.09) |
| University | 319/345 (92.5%) | 2.23 (1.25,3.99) |
| Non active worker | 648/1029 (63.0%) | 1 |
| Active worker | 960/1094 (87.7%) | 1.43 (1.06,1.93) |
| Severe persistent | 28/90 (31.1%) | 1 |
| Moderate persistent | 449/706 (63.6%) | 2.24 (1.14,4.41) |
| Mild persistent | 655/774 (84.6%) | 3.35 (1.66,6.75) |
| Intermittent | 476/554 (85.9%) | 2.65 (1.28,5.48) |
| Yes | 207/307 (67.4%) | 1 |
| No | 1,394/1,810 (77.0%) | 2.04 (1.46,2.83) |
| >1.50 | 437/792 (55.2%) | 1 |
| 0.75-1.50 | 464/561 (82.7%) | 1.80 (1.33,2.44) |
| <0.75 | 708/772 (91.7%) | 2.78 (1.99,3.88) |
| Yes | 54/179 (30.2%) | 1 |
| No | 1,555/1,946 (79.9%) | 2.05 (1.30,3.25) |
| Yes | 503/810 (62.1%) | 1 |
| No | 1,106/1,315 (84.1%) | 1.37 (1.03,1.81) |
| Female | 883/1,227 (72.0%) | 1 |
| Male | 726/898 (80.8%) | 1.84 (1.41,2.41) |
| ≥ 60 years | 335/638 (52.5%) | 1 |
| 40 to 59 years | 551/704 (78.3%) | 1.35 (0.98,1.87) |
| 18 to 39 years | 723/783 (92.3%) | 2.37 (1.62,3.47) |
| None | 74/170 (43.5%) | 1 |
| Primary | 613/900 (68.1%) | 2.04 (1.33,3.12) |
| Secondary | 600/706 (85.0%) | 2.18 (1.36,3.49) |
| University | 319/345 (92.5%) | 2.55 (1.49,4.37) |
| Rural | 632/859 (73.6%) | 1 |
| Urban | 977/1265 (77.2%) | 1.28 (1.01,1.62) |
| Severe persistent | 28/90 (31.1%) | 1 |
| Moderate persistent | 449/706 (63.6%) | 1.74 (0.96,3.15) |
| Mild persistent | 655/774 (84.6%) | 2.61 (1.40,4.87) |
| Intermittent | 476/554 (85.9%) | 2.27 (1.19,4.33) |
| Yes | 207/307 (67.4%) | 1 |
| No | 1,394/1,810 (77.0%) | 5.57 (4.08,7.59) |
| >1.50 | 437/792 (55.2%) | 1 |
| 0.75-1.50 | 464/561 (82.7%) | 1.36 (1.01,1.83) |
| <0.75 | 708/772 (91.7%) | 1.66 (1.21,2.28) |
| Yes | 54/179 (30.2%) | 1 |
| No | 1,555/1,946 (79.9%) | 2.09 (1.36,3.22) |
| Yes | 503/810 (62.1%) | 1 |
| No | 1,106/1,315 (84.1%) | 1.32 (1.02,1.72) |
*Adjusted Odds Ratio (Adjusted by all the variables in the Table 1).
NS, Crude Odds Ratio non significant; BMI, Body mass index; SABA, Short-acting beta2 agonists; LABA, Long-acting beta2 agonists; SD, Standard Deviation; IC, Inhaled corticosteroids.
Factors associated with health-related quality of life: VAS scale (0 = worst health state, 100 = best health state); (n = 2034)
| | | ||
|---|---|---|---|
| | | | |
| ≥ 60 years | 609 | 62.38 (17.46) | |
| 40 to 59 years | 675 | 68.93 (16.66) | 1.78 (−0.38,3.94) |
| 18 to 39 years | 750 | 76.34 (15.33) | 4.99 (2.63,7.37) |
| | | | |
| None | 162 | 58.57 (18.52) | |
| Primary | 865 | 66.12 (17.18) | 2.41 (−0.63,5.44) |
| Secondary | 667 | 73.48 (16.02) | 4.96 (1.64,8.28) |
| University | 336 | 76.87 (14.92) | 6.30 (2.69,9.90) |
| | | | |
| Severe persistent | 87 | 46.78 (17.21) | |
| Moderate persistent | 672 | 65.45 (16.86) | 9.01 (5.07,12.96) |
| Mild persistent | 754 | 72.97 (15.12) | 11.40 (7.28,15.52) |
| Intermittent | 520 | 74.26 (16.96) | 9.49 (5.22,13.76) |
| | | | |
| Current or former | 753 | 68.47 (17.02) | |
| Never | 1,279 | 70.43 (17.58) | 2.51 (1.13,3.89) |
| | | | |
| Yes | 296 | 61.47 (18.61) | |
| No | 1,731 | 71.10 (16.75) | 6.17 (4.31,8.03) |
| | | | |
| < 8 | 511 | 65.25 (17.78) | |
| ≥ 8 | 1,521 | 71.23 (16.98) | 4.02 (2.54,5.50) |
| | | | |
| >1.50 | 762 | 58.94 (16.38) | |
| 0.75-1.50 | 541 | 72.59 (13.89) | 9.48 (7.53,11.44) |
| <0.75 | 731 | 78.79 (14.48) | 13.26 (11.22,15.29) |
Score of VAS scale, and probability of obtaining values greater than the mean on the VAS. Multivariate analysis.
*Adjusted by all the variables in the Table 1.
N, number of cases; VAS, Visual Analogue Scale; CI, Confidence interval; BMI, Body mass index; SABA, Short-acting beta2 agonists; LABA, Long-acting beta2 agonists; IC, Inhaled corticosteroids.